A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. [electronic resource]
Producer: 20061122Description: 729-35 p. digitalISSN:- 0160-2446
- Animals
- Aspartic Acid Endopeptidases -- biosynthesis
- Blood Pressure
- Blotting, Western
- Calcium-Binding Proteins -- biosynthesis
- Cardiomyopathies -- drug therapy
- Diabetes Complications -- drug therapy
- Diabetes Mellitus, Experimental
- Down-Regulation
- Endothelin Receptor Antagonists
- Endothelin-Converting Enzymes
- Heart Rate
- Male
- Metalloendopeptidases -- biosynthesis
- Myocardium -- metabolism
- Nitric Oxide Synthase Type II -- biosynthesis
- Organ Size
- Oxidative Stress
- Pyrazoles -- therapeutic use
- RNA, Messenger -- analysis
- Rats
- Rats, Sprague-Dawley
- Reverse Transcriptase Polymerase Chain Reaction
- Ryanodine Receptor Calcium Release Channel -- biosynthesis
- Sarcoplasmic Reticulum Calcium-Transporting ATPases -- biosynthesis
- Streptozocin
- Tacrolimus Binding Protein 1A -- biosynthesis
- Up-Regulation
- Vasoconstrictor Agents -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.